Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?
- 1 July 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 2 (4) , 297-304
Abstract
Background— Randomized trials and observational studies support using an international normalized ratio (INR) target of 2.0 to 3.0 for preventing ischemic stroke in atrial fibrillation. We assessed whether the INR target should be adjusted based on selected patient characteristics. Methods and Results— We conducted a case–control study nested within the ATRIA cohort’s 9217 atrial fibrillation patients taking warfarin to define the relationship between INR level and the odds of thromboembolism (TE; mainly stroke) and of intracranial hemorrhage (ICH) relative to INR 2.0 to 2.5. We identified 396 TE cases and 164 ICH cases during follow-up. Each case was compared with 4 randomly selected controls matched on calendar date and stroke risk factors using matched univariable analyses and conditional logistic regression. We explored modification of the INR–outcome relationships by the following stroke risk factors: prior stroke, age, and CHADS 2 risk score. Overall, the odds of TE were low and stable above INR 1.8. Compared with INR 2.0 to 2.5, the relative odds of TE increased strikingly at INR 3.5 (eg, odds ratio, 3.56; 95% CI: 1.70 to 7.46, at INR 3.6 to 4.5). The relative odds of ICH were consistently low at INR 2 risk score. Conclusions— Our results confirm that the current standard of INR 2.0 to 3.0 for atrial fibrillation falls in the optimal INR range. Our findings do not support adjustment of INR targets according to previously defined stroke risk factors.Keywords
This publication has 49 references indexed in Scilit:
- Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial FibrillationCirculation: Cardiovascular Quality and Outcomes, 2008
- Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysisCanadian Medical Association Journal, 2008
- Comparison of Risk Stratification Schemes to Predict Thromboembolism in People With Nonvalvular Atrial FibrillationJACC, 2008
- Death and Disability from Warfarin-Associated Intracranial and Extracranial HemorrhagesThe American Journal of Medicine, 2007
- ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial FibrillationCirculation, 2006
- Atrial Fibrillation and Stroke in the General Medicare PopulationStroke, 2006
- Age and the Risk of Warfarin‐Associated Hemorrhage: The Anticoagulation and Risk Factors In Atrial Fibrillation StudyJournal of the American Geriatrics Society, 2006
- Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)American Heart Journal, 2006
- Risk of bleeding with long-term antithrombotic therapy in atrial fibrillationEuropean Heart Journal Supplements, 2005
- Bleeding complications in oral anticoagulant therapy. An analysis of risk factorsArchives of internal medicine (1960), 1993